Immune Response to COVID-19 Vaccine in Recipients of Living Donor Liver Transplantation

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

50 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-09-15

Study Completion Date

2023-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A prospective cohort study to evaluate the response to COVID-19 vaccine in liver transplantation patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

De Novo Metabolic Syndrome in Liver Transplant Patients After Immunosuppression Withdrawal

NCT05808192

Single Transplant 5 Years of Follow-up After Transplant, in Which an Attempt Was Made to Suspend IS

COMPLETED

Lipids and Neurological Complications in Liver Transplantation

NCT02544919

Neurological Complications

UNKNOWN PHASE4

Evaluation of Long Haul COVID-19 and Vaccine Immunogenicity in Patients With Liver Disease

NCT05107271

COVID-19 Chronic Liver Failure Cirrhosis, Liver +2 more

COMPLETED

The Second COVID-19 Wave: Collateral Impact on Patients of Liver Disease

NCT05167305

Liver Diseases

COMPLETED

Effect of N_Acetylcysteine on Liver Functions in Donors in Living Liver Transplantation

NCT03634566

Liver Transplant; Complications

COMPLETED PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

fifty living donor liver transplantation recipients during maintenance immunosuppression phase will be vaccinated against COVID-19 followed by assessment of immune response to the vaccine and further investigation of correlation of immune response to genetic polymorphisms of HLA DRB1(rs2647087) gene and IL-18 (rs187238 and rs917997) gene.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Liver Transplant

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Vaccinated group

Fifty living donor liver transplantation recipients on maintenance immunosuppressive regimen who would receive COVID-19 vaccine at least 3 months postoperatively.

COVID-19 Vaccine

Intervention Type BIOLOGICAL

Severe acute respiratory syndrome- coronavirus-2 (SARS-CoV-2)vaccine according to vaccine availability in the Egyptian ministry of health.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

COVID-19 Vaccine

Severe acute respiratory syndrome- coronavirus-2 (SARS-CoV-2)vaccine according to vaccine availability in the Egyptian ministry of health.

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age\>18
* At least 3 month post transplantation

Exclusion Criteria

* pediatric recipients
* Active covid infection at the time of the study
* Pregnancy
* Allergy to any ingredients included in the vaccine
* Lactation in first six month of delivery
* Active Acute cellular rejection proven by liver biopsy
* Acute Febrile state with either leucopenia or leucocytosis
* High dose of corticosteroid at study timing (pulse methyl prednisolone)

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No